Intra-Cellular Therapies Inc.
This article was originally published in Start Up
Executive Summary
Built on technology from the lab of Nobel laureate Paul Greengard, PhD, Intra-Cellular Therapies Inc. aims to develop small-molecule compounds that modify intracellular responses to endogenous neurotransmitters as therapeutics for Parkinson's disease, depression, schizophrenia and other CNS disorders.
You may also be interested in...
Biocortech
Biocortech was established in November 2001 to commercialize the fruits of the founders' research into the underlying causes of treatment-resistant forms of CNS diseases such as depression and schizophrenia. The company's aim is to develop effective therapies for these and other diseases associated with the pre-frontal cortex of the brain, such as bipolar disorder and cognitive and sexual disorders.
Functional Genetics Inc.
Functional Genetics has developed a method for simultaneously knocking out both alleles of a gene, even when that gene is not known. The technology enables the company to better associate gene with disease process and function up front in the drug discovery process.
Functional Genetics Inc.
Functional Genetics has developed a method for simultaneously knocking out both alleles of a gene, even when that gene is not known. The technology enables the company to better associate gene with disease process and function up front in the drug discovery process.